TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TT-01488’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TT-01488 is under development for the treatment of BTK mutated B-Cell non-Hodgkin lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma, Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma) follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large-b-cell lymphomas (DLBCL) and B-cell lymphomas. The drug candidate acts by targeting Bruton's tyrosine kinase (BTK). It is administered through oral route.
TransThera Sciences (Nanjing) overview
TransThera Sciences (Nanjing) (TransThera Sciences) is a biotechnology company, dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via the internal research platform and open innovation. The company develops and commercializes small molecule therapeutic agents for cancer, cardiovascular and inflammatory diseases. It focuses on the discovery and development of highly differentiated small-molecule new drugs and serving the medical needs of patients worldwide. Its oncology product portfolio includes TT-00420, TT-00434, TT-01488, TT-009373, and TT-ROMI. Its non-oncology products are TT-00920, TT-01688, TT-01025 and TT-RIAN. TransThera Sciences is headquartered in Nanjing, Jiangsu, China.
For a complete picture of TT-01488’s drug-specific PTSR and LoA scores, buy the report here.